Cadila Pharmaceuticals Launches Avastin Biosimilar in India


Cadila Pharmaceuticals has launched a bevacizumab biosimilar referencing Avastin in India. Bevacizumab is used for the treatment of colorectal, breast, and lung cancers, among others.

Ahmedabad-based Cadila Pharmaceuticals said it has launched a bevacizumab biosimilar (Bevaro) on the Indian market for the treatment of multiple cancers.

The biosimilar referencing Genentech’s Avastin is used in patients with ovarian cancer, glioblastoma multiforme, colorectal cancer, breast cancer, lung cancer, cervical cancer, and kidney cancer.

Bevaro will be made available in a single-dose vials of 100 mg and 400 mg.

Cadila “has always been focused in making sure high quality, affordable and life-saving treatments are within the reach of patients. Biosimilar products like Bevaro are safe and more efficacious compared to conventional treatment medicines,” the company said in a statement.

Cadila said it plans to launch multiple other biosimilar products in 2020 for the Indian market.

More About Cadila Pharmaceuticals

Cadila is one of the largest privately held pharmaceutical companies in India and was founded in 1951. It has more than 850 formulation products and manufactures 38 active pharmaceutical ingredients. Its therapeutic specialties include cardiovascular, gastrointestinal, analgesic, anti-infective and antibiotic, respiratory, antidiabetic, immunology, and oncology products.

The company has seen setbacks from the coronavirus disease 2019 (COVID-19) this year. In May, its Dholka formulations plant in Ahmedabad was shut down after more than 2 dozen employees tested positive for COVID-19, according to Reuters.

The plant was subjected to deep sanitization to bring it back up to health standards, according to a financial press report.

Companies in India have been eager to get a share of the global biosimilars market. Biocon has been a standout example of an Indian company that has succeeded in broadening its scope to an international standing.

Related Videos
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Related Content
© 2023 MJH Life Sciences

All rights reserved.